Difference between revisions of "Part:BBa K3096017:Design"

 
m (→‎References)
 
(One intermediate revision by the same user not shown)
Line 13: Line 13:
 
===Source===
 
===Source===
  
−
https://www.tandfonline.com/doi/abs/10.1080/1061186X.2017.1289537?journalCode=idrt20
+
 
 +
 
 +
Teuta Opačak-Bernardi and Jung Su Ryu and Drazen Raucher. Effects of cell penetrating Notch inhibitory peptide conjugated to elastin-like polypeptide on glioblastoma cells. Journal of Drug Targeting. Volume 25. Number 6. pages 523-531. 2017. Taylor & Francis.10.1080/1061186X.2017.1289537
  
 
===References===
 
===References===
 +
Teuta Opačak-Bernardi and Jung Su Ryu and Drazen Raucher. Effects of cell penetrating Notch inhibitory peptide conjugated to elastin-like polypeptide on glioblastoma cells. Journal of Drug Targeting. Volume 25. Number 6. pages 523-531. 2017. Taylor & Francis.10.1080/1061186X.2017.1289537

Latest revision as of 12:29, 15 October 2019


SynB1 - cell penetrating peptide


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    INCOMPATIBLE WITH RFC[25]
    Illegal AgeI site found at 46
  • 1000
    COMPATIBLE WITH RFC[1000]


Design Notes

sequence was taken from Opacak-Bernardi.


Source

Teuta Opačak-Bernardi and Jung Su Ryu and Drazen Raucher. Effects of cell penetrating Notch inhibitory peptide conjugated to elastin-like polypeptide on glioblastoma cells. Journal of Drug Targeting. Volume 25. Number 6. pages 523-531. 2017. Taylor & Francis.10.1080/1061186X.2017.1289537

References

Teuta Opačak-Bernardi and Jung Su Ryu and Drazen Raucher. Effects of cell penetrating Notch inhibitory peptide conjugated to elastin-like polypeptide on glioblastoma cells. Journal of Drug Targeting. Volume 25. Number 6. pages 523-531. 2017. Taylor & Francis.10.1080/1061186X.2017.1289537